Search
Search Results
-
Patients with longstanding psoriatic arthritis can achieve DAPSA remission or low disease activity and it correlates to better functional outcomes: results from a Latin-American real-life cohort
BackgroundPatients with psoriatic arthritis (PsA) experience reduced physical function and impaired quality of life. Better patient-reported...
-
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
ObjectiveAssess relationship between earlier clinical improvement and radiographic progression (RP) over 2 years in guselkumab-treated patients with...
-
Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
IntroductionThis study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA).
...
-
Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study
BackgroundUpadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval...
-
Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice
IntroductionOur aim was to investigate the efficacy and safety of upadacitinib (UPA) in patients with either oligo- or polyarticular active psoriatic...
-
Filling the “GAP” in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint
IntroductionSome retrospective data sources, such as electronic health records in the USA, report composite outcome measures not fully validated in...
-
The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study
IntroductionGuselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate...
-
Glucocorticoid use in psoriatic arthritis and treatment outcomes: does the gender have a role?
BackgroundSystemic glucocorticoids are commonly used in practice in the treatment of psoriatic arthritis. However, authorities advise against...
-
Radiological progression and predictive factors in psoriatic arthritis: insights from a decade-long retrospective cohort study
ObjectivesRadiological alterations in psoriatic arthritis (PsA) are an established phenomenon frequently observed throughout the disease course. Our...
-
Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease
There are limited data regarding cycling between interleukin-17 (IL-17) inhibitors in psoriatic arthritis (PsA). We aimed to report the efficacy of...
-
Serum Interleukin-34 in Psoriatic arthritis patients and its correlation with disease 1 activity, and subclinical atherosclerosis
BackgroundPsoriatic arthritis (PsA) is a chronic multi-domains autoimmune inflammatory disorder. Patients with PsA have a significant prevalence of...
-
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
IntroductionThe efficacy and safety of ixekizumab, an anti-interleukin-17A antibody, in patients with severe symptoms of psoriatic arthritis are...
-
Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence
ObjectiveThis systematic literature review aimed to identify and summarise real-world observational studies reporting the type, prevalence and/or...
-
Serum interleukin-23 levels: relation to depression, anxiety, and disease activity in psoriatic arthritis patients
ObjectivesAssessment of serum levels of IL-23 in PsA patients and its correlation with depression, anxiety, and disease activity.
Methods ...
-
Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
IntroductionIxekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the...
-
Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion
Evidence-based treatment recommendations for psoriatic arthritis (PsA) suggest that treatment should be individualised but acknowledge the difficulty...
-
Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting
IntroductionPsoriasis (PsO) is an immune-mediated chronic inflammatory disease that results in severe outcomes that impact the patient’s quality of...
-
Validity and psychometric characteristics of the self-administered comorbidity questionnaire in patients with psoriatic arthritis
The study aimed to translate and cross-culturally adapt the self-comorbidity questionnaire (SCQ) into Turkish and investigate the validity and...
-
Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis
BackgroundPsoriatic Arthritis (PsA) is an immune-mediated disease with heterogenous symptoms indicating differences in the underlying...
-
Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study
BackgroundWe explored whether serum cytokines could be used as biomarkers for optimal use of tumor necrosis factor inhibitors (TNF-i) and interleukin...
